Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips Sells 26,735 Shares of Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,735 shares of Accelerate Diagnostics stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $0.78, for a total transaction of $20,853.30. Following the transaction, the chief executive officer now directly owns 162,919 shares of the company’s stock, valued at $127,076.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Jack Phillips also recently made the following trade(s):

• On Friday, April 12th, Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock. The shares were sold at an average price of $0.86, for a total transaction of $22,828.70.
• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total transaction of $642.20.

Accelerate Diagnostics Stock Up 4.5 %

Shares of AXDX stock opened at $0.77 on Friday. The company has a 50 day moving average price of $1.00 and a 200-day moving average price of $3.20. Accelerate Diagnostics, Inc. has a 52 week low of $0.73 and a 52 week high of $11.90. The firm has a market capitalization of $16.68 million, a PE ratio of -0.16 and a beta of 0.52.

Institutional Trading of Accelerate Diagnostics

Several large investors have recently added to or reduced their stakes in the business. Griffin Asset Management Inc. boosted its position in shares of Accelerate Diagnostics by 11.0% in the first quarter. Griffin Asset Management Inc. now owns 1,354,254 shares of the medical research company’s stock worth $1,341,000 after purchasing an additional 134,530 shares during the period. Tejara Capital Ltd purchased a new position in shares of Accelerate Diagnostics in the third quarter worth $78,000. Sonora Investment Management Group LLC purchased a new position in shares of Accelerate Diagnostics in the third quarter worth $63,000. TCI Wealth Advisors Inc. purchased a new position in shares of Accelerate Diagnostics in the third quarter worth $337,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Accelerate Diagnostics by 31.8% in the second quarter. Geode Capital Management LLC now owns 655,906 shares of the medical research company’s stock worth $531,000 after buying an additional 158,383 shares in the last quarter. 17.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Craig Hallum decreased their target price on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a report on Monday, April 1st. StockNews.com assumed coverage on shares of Accelerate Diagnostics in a report on Friday, April 12th. They issued a “hold” rating for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.